APA (7th ed.) Citation

MK, A., TP, V., I, B., I, S., K, G., V, P., . . . P, T. (2018). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematological oncology, 36(1), 174. https://doi.org/10.1002/hon.2383

Chicago Style (17th ed.) Citation

MK, Angelopoulou, et al. "Brentuximab Vedotin in Relapsed/refractory Hodgkin Lymphoma. The Hellenic Experience." Hematological Oncology 36, no. 1 (2018): 174. https://doi.org/10.1002/hon.2383.

MLA (9th ed.) Citation

MK, Angelopoulou, et al. "Brentuximab Vedotin in Relapsed/refractory Hodgkin Lymphoma. The Hellenic Experience." Hematological Oncology, vol. 36, no. 1, 2018, p. 174, https://doi.org/10.1002/hon.2383.